Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
3.930
-0.070 (-1.75%)
At close: Jun 2, 2026, 4:00 PM EDT
3.940
+0.010 (0.25%)
Pre-market: Jun 3, 2026, 4:02 AM EDT
Aquestive Therapeutics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Aquestive Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $8.89. The average 1-year stock price forecast is 126.21% higher than the current stock price, while the lowest is $6.00 (+52.67%) and the highest is $11 (+179.90%).
Price Target: $8.89 (+126.21%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aquestive Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 2 | 1 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 8 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Reiterates $9 | Buy | Reiterates | $9 | +129.01% | May 15, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Reiterates $9 | Buy | Reiterates | $9 | +129.01% | May 15, 2026 |
| Lake Street | Lake Street | Buy Maintains $6 | Buy | Maintains | $6 | +52.67% | May 15, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $8 | Buy | Reiterates | $8 | +103.56% | May 15, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $8 | Buy | Reiterates | $8 | +103.56% | May 15, 2026 |
Financial Forecast
Revenue This Year
50.52M
from 44.55M
Increased by 13.40%
Revenue Next Year
71.91M
from 50.52M
Increased by 42.36%
EPS This Year
-0.41
from -0.78
EPS Next Year
-0.39
from -0.41
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 55.3M | ||
| Avg | 50.5M | ||
| Low | 47.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 24.2% | ||
| Avg | 13.4% | ||
| Low | 6.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.24 | ||
| Avg | -0.41 | ||
| Low | -0.48 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by S&P Global Market Intelligence. The data is sourced from Wall Street analysts. Data sources.